Long-term pharmacologic management of atrial fibrillation in the elderly

American Journal of Geriatric Cardiology

Volumn 11, Issue 4, 2002, Pages

  Waldo, Albert L ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; DOFETILIDE; FLECAINIDE; MORACIZINE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL; VERAPAMIL; WARFARIN;

AGED; ARTICLE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DRUG INDUCED DISEASE; DRUG SAFETY; ELDERLY CARE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; LONG TERM CARE; PHARMACEUTICAL CARE;

EID: 0036314397     PISSN: 10767460     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1076-7460.2002.00033.x     Document Type: Article

References (50)

1. Modern management of atrial fibrillation
2. Management of atrial fibrillation: The need for AFFIRMative action. Atrial fibrillation follow-up investigation of rhythm management
3. Atrial fibrillation follow up investigation of rhythm management - The AFFIRM study design
4. Survival in patients presenting with atrial fibrillation: The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study
5. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats
6. Transesophageal echocardiography-guided cardioversion of atrial fibrillation or flutter
7. Anticoagulation to prevent stroke in atrial fibrillation and its implications for managed care
8. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation
9. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK study
10. Stroke Prevention in Atrial Fibrillation Study. Final results
11. Secondary prevention in nonrheumatic atrial fibrillation after transient ischemic attack or minor stroke
12. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomized clinical trial
13. Prophylactic drug therapy after cardioversion of atrial fibrillation or flutter
14. Atrial fibrillation: Current understanding and research imperatives
15. Drugs after cardioversion to prevent relapses of chronic atrial fibrillation or flutter
16. Measures of drug efficacy in treating atrial fibrillation
17. Prevention of recurrent atrial fibrillation with chronic dual-site atrial pacing
18. Long-term outcome of patients with drug-refractory atrial flutter and fibrillation after single- and dual-site right atrial pacing for arrhythmia prevention
19. The efficacy of pacing therapies for treating atrial tachyarrhythmias in patients with ventricular arrhythmias receiving a dual-chamber implantable cardioverter-defibrillator
20. Initial results of ADOPT (Atrial Dynamic Overdrive Pacing Trial)
21. Atrioverter: An implantable device for the treatment of atrial fibrillation
22. Hybrid pharmacologic and ablative therapy: A novel and effective approach for the management of atrial fibrillation
23. Drug treatment of atrial fibrillation in the managed care era
24. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation
25. Can antiarrhythmic drugs survive survival trials?
26. Dofetilide in patients with congestive heart failure and left ventricular dysfunction
27. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: A randomized trial
28. Azimilide Post Infarct Survival Evaluation (ALIVE): Azimilide does not affect mortality in post myocardial infarction patients
29. Efficacy and safety of oral dofetilide in converting and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter
30. Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias
31. Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter
32. Controlled clinical trial of sotalol for one year after myocardial infarction
33. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction
34. Efficacy and safety of moricizine in the maintenance of sinus rhythm in patients with recurrent atrial fibrillation
35. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials
36. Atrial fibrillation
37. Mechanism of arrhythmias in ventricular hypertrophy
38. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
39. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials
40. Proarrhythmia during drug treatment of supraventricular tachycardia: Paradoxical risk of sinus rhythm for sudden death
41. Prevention of symptomatic recurrence of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo using transtelephonic monitoring
42. Flecainide acetate prevents recurrence of paroxysmal supraventricular tachycardia
43. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation
44. Safety and tolerability of long term propafenone therapy for supraventricular tachyarrhythmia
45. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins
46. Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation
47. Radio-frequency catheter modification of atrioventricular conduction to control the ventricular rate during atrial fibrillation
48. Long term follow up of patients undergoing AVjunctional ablation
49. Management of patients with atrial fibrillation. A statement for healthcare professionals from the subcommittee on electrocardiography and electrophysiology, American Heart Association
50. Nonpharmacological approaches to atrial fibrillation